Table 1 Comparison of baseline characteristics between groups stratified by tertile of SHR
Variables | Overall (n = 2841) | T1 (n = 947) SHR < 0.929 | T2 (n = 946) 0.929 ≤ SHR < 1.176 | T3 (n = 948) SHR ≥ 1.176 | P value |
|---|---|---|---|---|---|
Age, years | 62.27 ± 12.18 | 61.67 ± 11.82 | 61.81 ± 12.53 | 63.32 ± 12.12 | 0.005 |
Male, n (%) | 2347(82.6%) | 810(85.5%) | 794(83.9%) | 743(78.4%) |  < 0.001 |
SBP, mm Hg | 122 ± 22 | 123 ± 21 | 122 ± 21 | 120 ± 22 | 0.019 |
DBP, mm Hg | 74 ± 14 | 74 ± 13 | 74 ± 13 | 73 ± 13 | 0.045 |
Heart rate | 80 ± 16 | 77 ± 14 | 80 ± 15 | 83 ± 17 |  < 0.001 |
Killip classification |  |  |  |  |  < 0.001 |
 I | 1973 (69.5%) | 692 (73.1%) | 687 (72.7%) | 594 (62.7%) |  |
 II | 586 (20.6%) | 184 (19.4%) | 186 (19.7%) | 216 (22.8%) |  |
 III | 157 (5.5%) | 40 (4.2%) | 47 (5.0%) | 70 (7.4%) |  |
 IV | 124 (4.4%) | 31 (3.3%) | 25 (2.6%) | 68 (7.2%) |  |
Medical history, n (%) | |||||
 Current smoker | 1179 (41.5%) | 423 (44.7%) | 409 (43.3%) | 347 (36.6%) |  < 0.001 |
 Hypertension | 1471(51.8%) | 468 (49.4%) | 488 (51.6%) | 515 (54.3%) | 0.101 |
 Diabetes mellitus | 882 (31.0%) | 257 (27.1%) | 245 (25.9%) | 380 (40.1%) |  < 0.001 |
 Hyperlipidemia | 361 (12.7%) | 129 (13.6%) | 127 (13.4%) | 105 (11.1%) | 0.180 |
 Atrial fibrillation | 91 (3.2%) | 24 (2.5%) | 37 (3.9%) | 30 (3.2%) | 0.235 |
 COPD | 65 (2.3%) | 22 (2.3%) | 26 (2.7%) | 17 (1.8%) | 0.379 |
 Prior MI | 698 (24.6%) | 267 (28.2%) | 208 (22.0%) | 223 (23.5%) | 0.005 |
 Prior PCI | 358 (12.6%) | 141 (14.9%) | 108 (11.4%) | 109 (11.5%) | 0.034 |
 Prior stroke | 202 (7.1%) | 60 (6.3%) | 61 (6.4%) | 81 (8.5%) | 0.109 |
Laboratory measurements | |||||
 WBC | 11.66 ± 3.99 | 10.97 ± 3.60 | 11.77 ± 3.78 | 12.23 ± 4.45 |  < 0.001 |
 Albumin | 35.10 ± 4.43 | 35.15 ± 4.64 | 35.28 ± 4.26 | 34.86 ± 4.37 | 0.112 |
 LVEF, % | 51.26 ± 11.81 | 52.44 ± 11.54 | 51.77 ± 11.35 | 49.56 ± 12.32 |  < 0.001 |
 Hemoglobin, g/L | 134.19 ± 19.29 | 134.33 ± 18.90 | 135.64 ± 18.12 | 132.61 ± 20.67 | 0.003 |
 Anemia | 916 (32.3%) | 302 (32.0%) | 290 (30.7%) | 324 (34.2%) | 0.247 |
 eGFR, mL/min | 84.23 ± 31.60 | 85.21 ± 31.23 | 87.72 ± 30.78 | 79.75 ± 32.28 |  < 0.001 |
 Admission blood glucose | 8.81 ± 4.10 | 6.48 ± 2.16 | 8.20 ± 2.89 | 11.75 ± 4.80 |  < 0.001 |
 HbA1c, % | 6.10 (5.70–7.00) | 6.20 (5.80–7.00) | 6.00 (5.60–6.70) | 6.10 (5.50–7.40) |  < 0.001 |
 Total cholesterol, mmol/L | 4.89 ± 1.24 | 4.90 ± 1.23 | 4.92 ± 1.19 | 4.84 ± 1.31 | 0.372 |
 LDL-C, mmol/L | 3.21 ± 1.00 | 3.25 ± 0.98 | 3.23 ± 0.96 | 3.17 ± 1.06 | 0.193 |
Medication use | |||||
 Aspirin | 2802 (98.6%) | 941 (99.4%) | 938 (99.2%) | 923 (97.4%) |  < 0.001 |
 Clopidogrel | 2496 (88.0%) | 838 (88.5%) | 814 (86.3%) | 844 (89.1%) | 0.145 |
 Statins | 2780 (97.9%) | 928 (98.0%) | 928 (98.1%) | 924 (97.6%) | 0.701 |
 β-blockers | 2324 (81.8%) | 781 (82.5%) | 775 (81.9%) | 768 (81.1%) | 0.738 |
 ACEI/ARB | 2254 (79.3%) | 758 (80.0%) | 745 (78.8%) | 751 (79.2%) | 0.782 |
Angiography | |||||
 Transradial assessment | 2436 (85.9%) | 851 (89.9%) | 819 (86.8%) | 766 (81.0%) |  < 0.001 |
 Multi-vessel stenosis, n (%) | 2087 (73.5%) | 707 (74.7%) | 679 (71.8%) | 701 (73.9%) | 0.335 |
 No. of stents | 1.49 ± 2.04 | 1.54 ± 0.91 | 1.52 ± 3.31 | 1.41 ± 0.84 | 0.304 |
 Length of stents, mm | 37.43 ± 24.60 | 39.62 ± 26.13 | 36.22 ± 23.20 | 36.47 ± 24.27 | 0.004 |
 Contrast volume, mL | 115.66 ± 41.24 | 118.69 ± 44.78 | 112.34 ± 36.73 | 115.91 ± 41.57 | 0.005 |
 Length of hospital stay, days | 6.00 (5.00 ~ 9.00) | 6.00 (5.00 ~ 8.00) | 7.00 (6.00 ~ 8.00) | 7.00 (6.00 ~ 11.00) |  < 0.001 |